Allogeneic blood transfusions: benefit, risks and clinical indications in countries with a low or high human development index. by Marcucci, C. et al.
British Medical Bulletin 2004; 70: 15–28 British Medical Bulletin, Vol. 70 © The British Council 2004; all rights reserved
DOI: 10.1093/bmb/ldh023
Allogeneic blood transfusions: benefit, risks 
and clinical indications in countries with 
a low or high human development index
Carlos Marcucci, Caveh Madjdpour and Donat R. Spahn
Department of Anesthesiology, University Hospital Lausanne (CHUV), CH-1011 Lausanne, 
Switzerland
The risks associated with allogeneic red blood cell (RBC) transfusions differ 
significantly between countries with low and high human development 
indexes (HDIs). In countries with a low HDI, the risk of infection (HIV, HBV, 
HCV and malaria) is elevated. In contrast, in countries with a high HDI, 
immunological reactions (haemolytic transfusion reactions, alloimmunization 
and immunosuppression) are predominant. Therefore the overall risk 
associated with RBC transfusions in low HDI countries is much more significant 
than that in high HDI countries. In view of these risks, the limited efficacy of 
RBC transfusion and its high costs, this procedure should be used sparingly 
and rationally. Therefore RBC transfusion protocols adapted to the local 
situation are essential. Such protocols should distinguish between physiological 
and haemoglobin-based transfusion triggers. In countries with a high HDI, 
relative tachycardia and hypotension, despite normovolaemia, ST-segment 
changes suggestive of myocardial ischaemia and an Hb level <6 g/dl can 
serve as general guidelines for transfusion. Higher haemoglobin transfusion 
triggers should be used for patients aged >80 years and those with coronary 
artery or cerebrovascular disease. In countries with a low HDI, clinical signs 
of circulatory failure or myocardial ischaemia and an Hb level <5 g/dl can 
serve as transfusion guidelines.
Introduction
Red blood cell (RBC) transfusions originating from an unrelated donor
are known as allogeneic RBC transfusions. In the West, i.e. in countries
with a high human development index (HDI), which is an index based
on life expectancy, literacy, enrolment in further education and per cap-
ita income, >50% of RBC transfusions are used in trauma and surgery
to compensate for major blood loss.1
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Benefits and risks of RBC transfusions
RBC transfusions are certainly beneficial in specific situations,2,3 but are
accompanied by many risks and side effects (Table 1). Several recent
studies have suggested that RBC transfusions are associated with major
adverse outcomes4–7 and high costs.8–10 In addition, RBC transfusions are
a limited resource and blood shortages can occur at times.11,12
The risk of viral transmission via RBC transfusions has decreased consid-
erably in recent years in high HDI countries,13 although new transfusion-
transmitted viruses have been discovered.14 In contrast, in countries with
medium or low HDIs, the risk of transmission of infectious diseases may
still be extremely high (Table 1).
Risks associated with blood transfusion
Most reviews consider risks on transfusion-transmissible infections and
immunological reactions, associated with RBC transfusions, that are
only applicable to Western countries, i.e. countries with a high HDI.13,15
Although 83% of the global population live in countries with med-
ium and low HDIs, they have access to only 40% of the global blood
Table 1 Relevant risks of transfusion of tested blood
Type of risk Estimate of current risk (infection rate per unit)
High HDI countries Low HDI countries
Infections
Viruses
HIV 1:1 468 00019–1:4 700 000 15 1:5020–1:257859
HBV 1:31 00015–1:205 00019 1:74–1:100060
HCV 1:1 935 00019–1:3 100 00015 1:257859
Bacteria (contamination) 1:2000–1:8000 (platelet pools) 




Malaria 1:4 000 00015 Up to 1:321
Prions





Acute haemolytic 1:13 00015 ?
Delayed haemolytic 1:900015 ?
Alloimmunization 1:160015 ?
Autoimmunization ? (recently identified as risk23) ?
Immunosuppression 1:161 ?
TRALI 1:70 00015 ?
Mistransfusion 1:14 000–1:18 00013 ?
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supply.16,17 Most notably, all blood donations in high HDI countries are
screened for transfusion-transmissible infections, whereas only 57% of
blood donations in medium and low HDI countries are tested.16,17 In
addition, the tests used for blood screening are not always comparable.
For example, only four of the 19 countries participating in the ‘Work-
shop of the Directors of National Blood Transfusion Services’, held in
Harare, Zimbabwe, in 2000, used p24 antigen testing for HIV blood
screening.18 Moreover, the blood donation rate per 1000 population is
almost 20 times higher in developed countries than in countries with a
low HDI. Regular non-remunerated volunteers, who are the safest
donors, provide 98% of donations in high HDI countries. In contrast,
such donors are a minority in low HDI countries where up to 60% of
donated blood comes from relatives of the anaemic patient or from paid
donors. This leads to a higher incidence and prevalence of transfusion-
related transmissible infections. However, the example of Zimbabwe
shows that, despite the high seroprevalence (25.8%) of viruses such as
HIV in the general population, the establishment of a well-organized
voluntary blood donor system can result in a low prevalence of HIV




The most striking differences in the risks associated with blood transfu-
sion between high and low HDI countries are found amongst viral infec-
tions. In recent years, the estimated risk of infection has decreased
sharply because improvements in test sensitivity have reduced infectious
window periods.19
In contrast with Western countries, the predominant risks in low HDI
countries are transfusion-transmitted viral infections such as HIV, hepa-
titis B virus (HBV) and hepatitis C virus (HCV) (Table 1). This is due to
the high seroprevalence of these diseases in the general population of
these countries, the poorly organized blood donation systems and the
low sensitivity of pathogen testing which results in HIV infection rates
of up to 1:50 per unit transfused.20
Bacterial contamination
Transfusion of contaminated platelets is one of the most common trans-
fusion-related risks in Western countries (1:2000–1:8000).15 The most
important cause is storage of platelets at 20–24 °C, which favours bacte-
rial growth. In contrast, storage of RBCs at 4 °C inhibits the growth of
Marcucci et al.
18 British Medical Bulletin 2004;70
many bacterial species, resulting in a much lower contamination rate of
down to 1:143000 per RBC unit transfused.15
Parasites
Although rare in high HDI countries, transfusion-transmitted malaria is
a major problem in highly endemic regions.21 Only a few studies have
addressed this problem, and most have focused on viral infections such
as HIV, HBV and HCV.
Prions
The first case of possible variant Creutzfeld-Jakob disease (vCJD) trans-
mitted by an RBC transfusion has recently been reported,22 although a
dietary infection with the agent of bovine spongiform encephalopathy
(BSE) cannot be completely ruled out. In view of the probable incubation
period of 6.5 years,22 it will be interesting to observe the evolution of the
current risk of transfusion-transmitted vCJD in the future.
Immunological risks
Haemolytic transfusion reactions
According to the data of the Quebec haemovigilance system the risk
estimate of acute haemolytic transfusion reactions is about 1:13000.15
In this study, about half the cases of acute haemolysis were due to
ABO incompatibilities.15 In contrast, delayed haemolytic transfusion
reactions are primarily caused by the presence of previously formed
antibodies.
Immunization
A recent study by Young et al.23 strongly suggests that autoimmunization
may be added to the risks of allogeneic blood transfusions. The underlying
pathomechanism is not currently understood, although conformational
changes of RBC epitopes through alloantibody binding may be a possible
trigger.23
Immunosuppression
Allogeneic RBC transfusions induce immunomodulation in the recipi-
ent.24–26 As a result, the incidence of postoperative infections is elevated
in transfused patients25 and cancer recurrence may be favoured.25,27
Transfusion-related acute lung injury (TRALI)
Allogeneic RBC transfusions may cause acute lung injury13,28,29 char-
acterized by the sudden onset of non-cardiogenic pulmonary oedema,
Blood transfusion in countries with high and low HDIs
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hypoxaemia, dyspoea and fever, often requiring intensive care treatment
including mechanical ventilation.
Mistransfusion
Mistransfusion occurs in 1:14000–1:18000 cases,13,15 with an approxi-
mate morbidity and mortality rate of 1:600000.30 Approximately 50%
of the errors occur at the clinical level and ~30% in the laboratory.13
Epidemiology
Three large observational studies indicating that allogeneic RBC transfu-
sions are independently associated with a higher mortality have recently
been published.4,6,31 Sophisticated statistical models were used in these
studies, but it is possible that the transfused patients were simply sicker
or more severely traumatized and that the increased mortality was not
due to a harmful effect of RBC transfusions but to the underlying medi-
cal condition of the transfused patients. Indeed, there is some evidence
that this was the case. Transfused patients were older, had lower haemo-
globin (Hb) and higher lactate levels at admission, had higher morbidity
and trauma scores, and were more frequently in shock at admission.4,6,31.
This potential confounding can only be avoided in prospective randomized
trials.32,33 The largest prospective randomized trial was performed by
Hebert et al.32 who compared a restrictive (Hb level <7.0 g/dl) with a
liberal (Hb level <9.0 g/dl) transfusion regimen and found a lower 30-day
mortality in the restrictive transfusion regimen in patients aged <55 years
and patients with a lower morbidity score. Therefore it seems likely that
RBC transfusions are efficacious only in very specific situations, such as
when pretransfusion oxygen (O2) delivery is low postoperatively,
34 or
that they are associated with enough significant side effects to result in
an overall adverse outcome.
Summary
A comparison of transfusion-related risks in high and low HDI countries
shows that there are major differences. In low HDI countries transfusion-
transmissible infections such as viral infections (HIV, HBV, HCV) and
parasitic infections (malaria) strongly dominate. In contrast, although
viral infections still occur in high HDI countries, the risk has been signi-
ficantly reduced by improved laboratory testing and donor screening.
The major risks of transfusion in Western countries are immunological
reactions (haemolytic transfusion reaction, immunomodulation, mis-
transfusion) and bacterial contamination of platelets.
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RBC transfusion protocols and transfusion triggers
Given the large number of risks and side effects, the high costs of RBC8–10
and the fact that RBC transfusions are a limited resource, the use of allo-
geneic RBC transfusion should be restricted (Table 2).
RBC transfusion protocols
Introduction of an RBC transfusion protocol has been reported to
reduce transfusion rates significantly.35 The protocol was very simple,
comprising only two rules: blood was only cross-matched for patients
Table 2 Haemoglobin-based and physiological transfusion triggers as a function of patient-related, logistical and 
geographical factors
NA, not applicable; PvO2, mixed venous oxygen partial pressure <32 mmHg; Ex-O2, oxygen extraction ratio >50%; VO2, oxygen
consumption >10%; CAD, coronary artery disease; CVD, cerebrovascular disease.
An RBC transfusion is indicated if one of the criteria listed (the Hb threshold, the circulation criterion, myocardial ischaemia or the PvO2,
Ex-O2 or VO2 criteria) is reached. Normovolaemia is assumed for all triggers, and anaemia should be the only probable cause.
*Includes all patients except the subcategories aged >80 years, those with CAD, those with CVD and those with fever/hypermetabolism.
†One may choose not to transfuse an individual patient without any physiological transfusion triggers.
‡Relative tachycardia is defined as a heart rate >120–130% of baseline (>110–130 bpm), and relative hypotension is defined as a mean
arterial blood pressure <70–80% of baseline or <60 mmHg (<55 mmHg in young healthy subjects, <70–80 mmHg in patients with CAD or
CVD and in hypertensive patients, and even higher in severely hyperstensive patients).
§A new ST-segment depression >0.1 mV or an ST-segment elevation >0.2 mV.
¶To be confirmed with ECG and/or troponin measurement, if possible, in a timely fashion.
Situation Patients Hb (g/dl) Circulation Myocardial ischaemia PvO2, Ex-O2, VO2
High HDI countries
Intraoperative, ICU All patients* 6† Relative 
tachycardia/hypotension‡
ST-segment changes§ Yes
>80 years 7 Relative 
tachycardia/hypotension‡
ST-segment changes§ Yes
CAD 8 Relative 
tachycardia/hypotension‡
ST-segment changes§ Yes
CVD 7 Relative 
tachycardia/hypotension‡
ST-segment changes§ Yes
Fever/hypermetabolism 7 Relative 
tachycardia/hypotension‡
ST-segment changes§ Yes
Ward All patients 6† Relative 
tachycardia/hypotension‡
Clinical signs¶ NA
>80 years 8 Relative 
tachycardia/hypotension‡
Clinical signs¶ NA
CAD 9 Relative 
tachycardia/hypotension‡
Clinical signs¶ NA
CVD 8 Relative 
tachycardia/hypotension‡
Clinical signs¶ NA




All situations All patients 5† Signs of circulatory failure Clinical signs¶ NA
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with a preoperative Hb level <11 g/dl, and patients only received allo-
geneic RBCs if the postoperative Hb level fell below 8.5 g/dl. The intro-
duction of these guidelines resulted in a reduction of the transfusion rate
from 35% to 11% and there were no adverse outcomes related to the
introduction of the protocol.
Boralessa and colleagues constructed a more complicated transfusion
algorithm based on preoperative Hb, postoperative blood loss and clin-
ical signs of anaemia.36 Particular attention was paid to education of
medical and nursing staff, with lectures on the rationale of the protocol.
After the introduction of these guidelines the number of patients trans-
fused after total knee replacement was reduced from 64% to 30%. Another
important observation was that in the first 24 h after surgery only eight
out of 13 patients who received RBC transfusions were transfused accord-
ing to the guidelines, a compliance rate of only 62%. Improvement of
compliance with the algorithm might have reduced the transfusion rate
even further.
RBC transfusion triggers
What should rational transfusion triggers be based on? The bulk of liter-
ature suggests that transfusion guidelines should not be reduced to a
trigger based on Hb levels alone. Physiological triggers rather than Hb
levels should guide transfusion therapy. Patient- and procedure-related
factors can influence the decision to use allogeneic RBC transfusions,
and the possible benefits must always be balanced against the possible
risks. Finally, logistical and geographical factors, although not usually
discussed in detail, are of major importance when establishing trans-
fusion protocols.
Hb-based RBC transfusion triggers
If the intravascular volume status is normal (normovolaemia), acute
anaemia is well tolerated by most individuals. To guarantee adequate
tissue oxygenation, the decrease in arterial oxygen content will be com-
pensated by an increase in cardiac output and in oxygen release by the
RBCs.37 In experimental settings volunteers have well tolerated HB
levels of 5 g/dl under normovolaemic conditions38 despite mild and tran-
sient cognitive dysfunction,39,40 although electrocardiographic signs of
ischaemia developed in a few subjects who developed tachycardia.38 All
of these adverse effects were readily reversible and resolved without
sequelae.
The effect of anaemia on morbidity and mortality in a surgical popula-
tion has been reported in a retrospective cohort study of 300 patients
who refused blood transfusions for religious reasons.41 Major morbidity
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started to increase with postoperative Hb levels <7 g/dl and certainly
increased with postoperative Hb levels <6 g/dl. Mortality started to increase
with postoperative Hb levels <6 g/dl and certainly increased with post-
operative Hb levels <5 g/dl.
Thus an Hb level <6 g/dl seems to be a strong transfusion trigger.42
However, under the controlled conditions of general anaesthesia and in
the absence of physiological and other transfusion triggers one may choose
not to transfuse an individual patient. At Hb levels >6 g/dl, the decision
to transfuse should be based on physiological signs of inadequate tissue
oxygenation, predictability and magnitude of blood loss, and logistical
factors.42
Physiological RBC transfusion triggers
Physiological transfusion triggers can be divided into signs of inadequate
oxygenation of either specific organs or the entire body.43 The latter include
relative tachycardia and hypotension, an exaggerated increase in O2
extraction, an exaggerated decrease in mixed-venous O2 partial pressure
and saturation, and a decrease in O2 consumption. Tachycardia and
hypotension, related to intraoperative blood loss, can only be considered
as transfusion triggers if hypovolaemia has been corrected with crystal-
loid or colloid fluids. For patients equipped with a pulmonary artery
catheter, a mixed-venous O2 partial pressure <4.3 kPa (32 mmHg) and
O2 extraction >50% are considered to be clear indications to transfuse.
Finally, an otherwise unexplained reduction in O2 consumption of >10%
is a reasonable transfusion trigger.43
The organs most at risk at critical Hb levels are the heart and the
brain. A new ST-segment depression >0.1 mV or a new ST-segment ele-
vation >0.2 mV for more than 1 min and new wall motion abnormalities
as detected by transoesophageal echocardiography are indicative of
myocardial ischaemia and are triggers for transfusion in the presence of
anaemia. All these signs are reversible if the Hb level is increased by only
1–2 g/dl.43,44
Cognitive dysfunction is a clear sign of cerebral impairment due to inade-
quate oxygenation but is of no use in a patient under general anaesthe-
sia. Other means of detecting intraoperative cerebral hypoxia are not
available or have not been validated.43 Therefore more liberal transfusion
triggers might be justified for patients with known or suspected cerebro-
vascular disease.
The adequacy of oxygenation of the splanchnic organs is also difficult
to monitor. However, these organs have been shown to support normovo-
laemic haemodilution very well, and so no specific monitoring is required.45
Perioperative and general transfusion guidelines should also take into
account patient-related factors such as comorbidities and age. In a review
of the literature, Khanna et al.46 found the following characteristics to be
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related to perioperative allogeneic RBC transfusion: preoperative anaemia,
age, female gender, small body stature, cardiovascular disease, liver disease
and other comorbidities such as rheumatoid arthritis and dementia.46 For
most of the factors identified, the evidence of any benefit of transfusion is
lacking and transfusions may not be justified. Female gender and small
body stature are probably related to a higher transfusion rate because of a
smaller circulating blood volume, and loss of similar amounts of blood will
lead to severe anaemia sooner than in heavier patients.
Patients with cardiovascular disease deserve special attention. First,
impaired contractility, valvular dysfunction or developing myocardial
ischaemia due to low Hb may compromise the compensatory increase in
cardiac output in anaemia. Carson et al.47 compared the mortality of 1958
Jehovah’s Witnesses with and without cardiovascular disease who under-
went surgery. The analysis indicated that the overall mortality increased
as Hb levels decreased, but the death rate of patients with concomitant
cardiovascular disease and preoperative anaemia increased more dra-
matically for each gram per decilitre of Hb decline. Although this study
clearly established the risk of perioperative anaemia for patients with
cardiovascular disease, it did not provide conclusive evidence that trans-
fusion diminishes this risk. On the contrary, randomized trials have
failed to show any benefit of transfusion in intensive care patients, with
or without cardiovascular disease, for Hb levels >7 g/dl.5,48 Spahn et al.49
found that patients scheduled for coronary artery bypass graft surgery
(CBAG), who were chronically β-blocked, tolerate acute normovolaemic
haemodilution to a Hb level of 9.9 g/dl. In response to haemodilution they
increased their cardiac index without an increase in heart rate and without
signs of ischaemia.
A positive correlation between transfusion and short term survival has
only been shown for patients with acute myocardial infarction. In a large
retrospective cohort study on 78974 patients with acute myocardial infarc-
tion, transfusion was related to a reduction in 30-day mortality for patients
if the haematocrit on admission was <33%.50 Conversely, transfusion was
related to an increased mortality for patients with haematocrit >36%.
Advancing age is related to a higher probability of coronary or cere-
brovascular sclerosis or other concomitant diseases. This is likely to lead
physicians to a more liberal use of allogeneic RBCs. However, scientific
data indicate that advancing age cannot be considered to be a transfusion
trigger. Casutt et al.3 examined the effects of blood transfusion on cardiac
index, oxygen delivery index and oxygen consumption index in 170
intensive care patients. They found that individual changes in these param-
eters were not related to preoperative ejection fraction or age. Elderly
patients reacted similarly to younger patients to acute normovolaemic
haemodilution (ANH). In a study of the tolerance of ANH in 20 elderly
patients (mean age 76 ± 2 years) without known cardiovascular disease,
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the preoperative Hb level was decreased from 11.6 ± 0.4 to 8.8 ± 0.3 g/dl
without any signs of inadequate oxygenation. Intraoperatively the mean
Hb level decreased even further to a mean of 7.7 g/dl, which was equally
well tolerated.51 In a retrospective cohort study of 8787 consecutive hip
fracture patients aged from 60 to 106 years, Carson et al.52 matched
patients who received RBCs in the perioperative period with patients
who did not receive RBCs. They were unable to demonstrate that transfu-
sion was related to a reduced 30- or 90-day postoperative mortality for
Hb levels as low as 8.0 g/dl. Almost all patients with Hb levels below
this value were transfused, and so no conclusions could be drawn for Hb
levels <8.0 g/dl.
Two recently published studies suggest that elderly patients may benefit
from relatively high Hb concentrations. Halm et al.53 noted that perio-
perative transfusion was related to lower re-admission rates after hip
fracture repair in a population with a mean age of 80 ± 9 years. This rela-
tionship was not valid if patients received RBCs for Hb triggers >10 g/dl.
Lawrence et al.54 found that, in patients aged 79 ± 9 years, higher post-
operative Hb levels (not necessarily in relation to an RBC transfusion)
were associated with a longer walking distance. However, neither study
found that morbidity, mortality or length of hospital stay was different
between patients with lower or higher Hb levels.
Finally, in patients with increased oxygen consumption, such as those
with a high fever or other hypermetabolic states, very low Hb levels (6 g/dl)
can theoretically be responsible for an oxygen demand–oxygen delivery
imbalance. Scientific data to back this hypothesis are lacking, but higher
Hb levels can be justified as a precaution.
Logistical and geographical factors
The Task Force on Blood Component Therapy of the American Society
of Anesthesiologists (ASA) conclude in their transfusion practice guide-
lines that transfusion is rarely indicated when the Hb level is >10 g/dl
and is almost always indicated when it is <6 g/dl.42 The decision as to
whether intermediate Hb levels justify or require RBC transfusion should
be based on the patient’s risk for complications of inadequate oxygenation.
When establishing perioperative transfusion guidelines, one must con-
sider that a patient under general anaesthesia has a decreased oxygen
consumption due to muscle paralysis, a hypometabolic state and pos-
sibly mild hypothermia. In addition, an anaesthesiologist continuously
monitors the patient and strives for an adequate blood pressure, avoids
tachycardia and achieves supranormal oxygenation by using supplemental
O2. In the postoperative period oxygen consumption can rise sharply
because of shivering, pain and other factors; the heart rate may be less
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strictly controlled and the oxygenation less perfect compared with the
intraoperative period. When we allow intraoperative Hb levels to fall as
low as 5–6 g/dl, close postoperative surveillance and frequent monitor-
ing of vital signs are necessary. Institutional guidelines should take into
account local logistical characteristics such as the level of knowledge and
availability of physician and nurse staff to guarantee patient safety, pos-
sibly justifying higher Hb transfusion triggers postoperatively.
Other logistical factors that may have to be taken into account are the
time required for blood products to be prepared and delivered, the safety
of local transfusion services and the age of the available RBCs. It has been
shown that RBCs that have been stored for >15 days do not augment
oxygen transport capacity immediately after transfusion55 and may even be
related to adverse outcome in critically ill patients.7
Geographical factors play an important role. Physicians in countries
with a low HDI are faced with completely different circumstances than
their colleagues in countries with a high HDI. The summary report of the
World Health Organization (WHO) Global Database on Blood Safety
indicates that the majority of low and medium HDI countries do not have
national policies and guidelines on clinical blood usage. The WHO spe-
cifically notes that, as most blood in developing countries is donated by
a family member or by paid donors, there are compelling social and
financial pressures for the use of blood, even if the patient does not
require transfusion.16,17 In view of these risks the WHO advocates that
transfusion should only be prescribed for conditions that might result in
mortality or significant morbidity, a very restrictive, but necessary,
attitude compared with the ASA guidelines.
In addition to problems of safety and access to blood products,
physicians in low HDI countries are confronted with many technical
problems. Fractioning of whole blood into its various components, stor-
age of blood products and transport of blood in accordance with the ‘cold
chain’ requires expensive equipment, maintenance and trained personnel.
Technical instruments to measure Hb levels are often not available. Sev-
eral strategies to differentiate moderate from severe anaemia have been
developed. The degree of pallor of the conjunctiva, tongue, palm of the
hand and nailbed has been linked to Hb levels. The severity of pallor is
described as definite pallor, probable pallor or none. This technique has
a specificity of 99% in detecting severe anaemia (Hb level <5 g/dl), but a
sensitivity of only around 50%.56 The efficacy of this technique is strongly
dependent on the experience of the physician and other confounding
factors, such as conjunctivitis. In 1995, Stott and Lewis57 developed the
Haemoglobin Colour Scale (HCS) to improve Hb estimation in settings
where laboratory facilities are not available. The HCS consists of six
standard colours varying from pale to dark red, corresponding to Hb levels
of 4, 6, 8, 10, 12 and 14 g/dl. To estimate the Hb level, a drop of blood
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is matched against the scale standards. For severe anaemia (<5 g/dl) the
HCS has a sensitivity of 92%, a specificity of 90%, a positive predictive
value of 49% and a negative predictive value of 99%.58 These techniques
have been developed for screening of patients in rural areas to guide hae-
matological therapy in pregnant woman and children with anaemia due
to malnutrition or malaria. The surgical population in low and medium
HDI countries consists mainly of trauma victims and young women
suffering from postpartum haemorrhage. Transfusion of RBCs can be
lifesaving for these patients (worldwide, postpartum haemorrhage is the
primary cause of perinatal maternal death). Because of the high risk
related to transfusion in these countries, the HCS might be of great use
in guiding perioperative fluid therapy but, to our knowledge, has not yet
been validated for this purpose.
Owing to the higher risk-to-benefit ratio related to RBC transfusions
in low HDI countries a more restrictive RBC transfusion policy is justi-
fied, and transfusions are indicated only when clinical signs of circulatory
failure or myocardial ischaemia are present or at an Hb level <5 g/dl. In
contrast, in high HDI countries where the overall risk associated with
RBC transfusions is lower, it is justifiable to administer RBC transfusions
more liberally when the patient develops signs of haemodynamic insta-
bility, ST-segment alterations suggestive of myocardial ischaemia or an Hb
level <6 g/dl. Transfusion may be justified at higher haemoglobin levels
if the patient has cardiovascular comorbidities or is aged >80 years.
In conclusion, the decision as to whether to transfuse a patient has to
be based on a careful evaluation of the benefits and possible risks. Most
importantly, logistical and geographical factors must be taken into account
when establishing an individual transfusion strategy based on patient-
related, physiological and Hb-based RBC transfusion triggers.
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